Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia

Current Opinion in Hematology

Volumn 13, Issue 3, 2006, Pages 142-148

  Sadelain, Michel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Anti sickling; Gene therapy; Globin gene transfer; Insertional mutagenesis; Lentiviral vector; RNA interference; Severe hemoglobinopathy; Stem cell therapy

Indexed keywords

BETA GLOBIN; GLOBIN; LENTIVIRUS VECTOR; RECOMBINANT BETA GLOBIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

BETA THALASSEMIA; BONE MARROW DONOR; CELL DIFFERENTIATION; CELL LINEAGE; CELL SPECIFICITY; ERYTHROID CELL; GENE EXPRESSION REGULATION; GENE INSERTION; GENE MUTATION; GENE THERAPY; GENE TRANSFER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN SYNTHESIS; HEMOGLOBINOPATHY; HLA MATCHING; HOMOLOGOUS RECOMBINATION; INSERTIONAL MUTAGENESIS; NONHUMAN; ORGAN DONOR; PRIORITY JOURNAL; REGULATOR GENE; REVIEW; RNA INTERFERENCE; SAFETY; SICKLE CELL ANEMIA; TRANSCRIPTION REGULATION; TRANSGENE; TREATMENT RESPONSE;

ANEMIA, SICKLE CELL; ANIMALS; BETA-THALASSEMIA; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLOBINS; HUMANS;

EID: 33646779583     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/01.moh.0000219658.57915.d4     Document Type: Review

References (92)

1. Weatherall DJ, Clegg JB. The thalassemia syndrome. Oxford: Blackwell Scientific; 1981.
2. Stamatoyannopoulos G, Nienhuis AW, Majerus P, Varmus H. The molecular basis of blood diseases. Philadelphia: WB Saunders; 1994.
3. Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet 2001; 2:245-255.
4. Steinberg MH, Forget BG, Higgs DR, Nagel RL. Disorders of hemoglobin: genetics, pathophysiology and clinical management. Cambridge: Cambridge University Press; 2001.
5. Cooley TB, Lee P. A series of cases of splenomegaly in children with anemia and peculiar bone changes. Trans Am Pediatr Soc 1925; 37:29.
6. Giardina PJ, Grady RW. Chelation therapy in beta-thalassemia: an optimistic update. Semin Hematol 2001; 38:360-366.
7. Giardini C, Lucarelli G. Bone marrow transplantation in the treatment of thalassemia. Curr Opin Hematol 1994; 1:170-176.
8. Boulad F, Giardina P, Gillio A, et al. Bone marrow transplantation for homozygous beta-thalassemia. The Memorial Sloan-Kettering Cancer Center experience. Ann N Y Acad Sci 1998; 850:498-502.
9. Lucarelli G, Clift RA, Galimberti M, et al. Bone marrow transplantation in adult thalassemic patients. Blood 1999; 93:1164-1167.
10. Tisdale J, Sadelain M. Toward gene therapy for disorders of globin synthesis. Semin Hematol 2001; 38:382-392.
11. Forget BG. Molecular mechanism of β thalassemia. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, editors. Disorders of haemoglobin: genetics, pathophysiology, and clinical management. Cambridge, UK: Cambridge University Press; 2001. pp. 252-276.
12. Pauling L, Itano HA, Singer SJ, Wells IC. Sickle cell anemia, a molecular disease. Science 1949; 110:543-546.
13. Swank RA, Stamatoyannopoulos G. Fetal gene reactivation. Curr Opin Genet Dev 1998; 8:366-370.
14. Platt OS, Orkin SH, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984; 74:652-656.
15. Charache S, Dover GJ, Moore RD, et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992; 79:2555-2565.
16. Atweh GF, Loukopoulos D. Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia. Semin Hematol 2001; 38:367-373.
17. Perrine SP, Castaneda SA, Boosalis MS, et al. Induction of fetal globin in β-thalassemia: cellular obstacles and molecular progress. Ann N Y Acad Sci 2005; 1054:257-265.
18. Stamatoyannopoulos G. Prospects for developing a molecular cure for thalassemia. Hematology 2005; 10 (Suppl 1):255-257.
19. Vermylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant 1998; 22:1-6.
20. Luzzatto L, Goodfellow P. Sickle cell anaemia: a simple disease with no cure. Nature 1989; 337:17-18.
21. Sadelain M. Genetic treatment of the haemoglobinopathies: recombinations and new combinations. Br J Haematol 1997; 98:247-253.
22. Leboulch P, Huang GM, Humphries RK, et al. Mutagenesis of retroviral vectors transducing human beta-globin gene and beta-globin locus control region derivatives results in stable transmission of an active transcriptional structure. EMBO J 1994; 13:3065-3076.
23. Sadelain M, Wang CH, Antoniou M, et al. Generation of a high-titer retroviral vector capable of expressing high levels of the human beta-globin gene. Proc Natl Acad Sci U S A 1995; 92:6728-6732.
24. Cone RD, Weber-Benarous A, Baorto D, Mulligan RC. Regulated expression of a complete human beta-globin gene encoded by a transmissible retrovirus vector. Mol Cell Biol 1987; 7:887-897.
25. Karlsson S, Papayannopoulou T, Schweiger SG, et al. Retroviral-mediated transfer of genomic globin genes leads to regulated production of RNA and protein. Proc Natl Acad Sci U S A 1987; 84:2411-2415.
26. Dzierzak EA, Papayannopoulou T, Mulligan RC. Lineage-specific expression of a human beta-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells. Nature 1988; 331:35-41.
27. Bender MA, Gelinas RE, Miller AD. A majority of mice show long-term expression of a human beta-globin gene after retrovirus transfer into hematopoietic stem cells. Mol Cell Biol 1989; 9:1426-1434.
28. Bodine DM, Karlsson S, Nienhuis AW. Combination of interleukins 3 and 6 preserves stem cell function in culture and enhances retrovirus-mediated gene transfer into hematopoietic stem cells. Proc Natl Acad Sci USA 1989; 86:8897-8901.
29. Plavec I, Papayannopoulou T, Maury C, Meyer F. A human beta-globin gene fused to the human beta-globin locus control region is expressed at high levels in erythroid cells of mice engrafted with retrovirus-transduced hematopoietic stem cells. Blood 1993; 81:1384-1392.
30. Chang JC, Liu D, Kan YW. A 36-base-pair core sequence of locus control region enhances retrovirally transferred human beta-globin gene expression. Proc Natl Acad Sci USA 1992; 89:3107-3110.
31. Novak U, Harris EA, Forrester W, et al. High-level beta-globin expression after retroviral transfer of locus activation region-containing human beta-globin gene derivatives into murine erythroleukemia cells. Proc Natl Acad Sci USA 1990; 87:3386-3390.
32. Higgs DR. Do LCRs open chromatin domains? Cell 1998; 95:299-302.
33. Bulger M, Groudine M. Looping versus linking: toward a model for long-distance gene activation. Genes Dev 1999; 13:2465-2477.
34. Grosveld F. Activation by locus control regions? Curr Opin Genet Dev 1999; 9:152-157.
35. Engel JD, Tanimoto K. Looping, linking, and chromatin activity: new insights into beta-globin locus regulation. Cell 2000; 100:499-502.
36. Navas PA, Li O, Peterson KR, et al. Activation of the beta-like globin genes in transgenic mice is dependent on the presence of the beta-locus control region. Hum Mol Genet 2002; 11:893-903.
37. de Krom M, van de Corput M, von Lindern M, et al. Stochastic patterns in globin gene expression are established prior to transcriptional activation and are clonally inherited. Mol Cell 2002; 9:1319-1326.
38. Bulger M, Sawado T, Schubeler D, Groudine M. ChlPs of the beta-globin locus: unraveling gene regulation within an active domain. Curr Opin Genet Dev 2002; 12:170-177.
39. Levings PP, Bungert J. The human beta-globin locus control region. Eur J Biochem 2002; 269:1589-1599.
40. Rivella S, Lisowski L, Sadelain M. Globin gene transfer: a paradigm for transgene regulation and vector safety. Gene Ther Reg 2003; 2:149-175.
41. Ellis J, Pasceri P, Tan-Un KC, et al. Evaluation of beta-globin gene therapy constructs in single copy transgenic mice. Nucleic Acids Res 1997; 25:1296-1302.
42. Ren S, Wong BY, Li J, et al. Production of genetically stable high-liter retroviral vectors that carry a human gamma-globin gene under the control of the alpha-globin locus control region. Blood 1996; 87:2518-2524.
43. Lung HY, Meeus IS, Weinberg RS, Atweh GF. In vivo silencing of the human gamma-globin gene in murine erythroid cells following retroviral transduction. Blood Cells Mol Dis 2000; 26:613-619.
44. Emery DW, Morrish F, Li Q, Stamatoyannopoulos G. Analysis of gamma-globin expression cassettes in retrovirus vectors. Hum Gene Ther 1999; 10:877-888.
45. Sabatino DE, Wong C, Cline AP, et al. A minimal ankyrin promoter linked to a human gamma-globin gene demonstrates erythroid specific copy number dependent expression with minimal position or enhancer dependence in transgenic mice. J Biol Chem 2000; 275:28549-28554.
46. Sabatino DE, Seidel NE, Aviles-Mendoza GJ, et al. Long-term expression of gamma-globin mRNA in mouse erythrocytes from retrovirus vectors containing the human gamma-globin gene fused to the ankyrin-1 promoter. Proc Natl Acad Sci USA 2000; 97:13294-13299.
47. Katsantoni EZ, Langeveld A, Wai AW. Persistent gamma-globin expression in adult transgenic mice is mediated by HPFH-2, HPFH-3, and HPFH-6 breakpoint sequences. Blood 2003; 102:3412-3419.
48. Fragkos M, Anagnou NP, Tubb J, Emery DW. Use of the hereditary persistence of fetal hemoglobin 2 enhancer to increase the expression of oncoretrovirus vectors for human gamma-globin. Gene Ther 2005; 12:1591-1600.
49. May C, Rivella S, Callegari J, et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 2000; 406:82-86.
50. Salmon P, Trono D. Lentiviral vectors for the gene therapy of lymphohematological disorders. Curr Top Microbiol Immunol 2002; 261:211-227.
51. Follenzi A, Naldini L. Generation of HIV-1 derived lentiviral vectors. Meth Enzymol 2002; 346:454-465.
52. Lewis PF, Emerman M. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol 1994; 68:510-516.
53. Goff SP. Intracellular trafficking of retroviral genomes during the early phase of infection: viral exploitation of cellular pathways. J Gene Med 2001; 3:517-528.
54. Miyoshi H, Blomer U, Takahashi M, et al. Development of a self-inactivating lentivirus vector. J Virol 1998; 72:8150-8157.
55. Miyoshi H, Smith KA, Mosier DE, et al. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 1999; 283:682-686.
56. Guenechea G, Gan OI, Inamitsu T, et al. Transduction of human CD34+ CD38- bone marrow and cord blood-derived SCID-repopulating cells with third-generation lentiviral vectors. MoI Ther 2000; 1:566-573.
57. Mangeot PE, Duperrier K, Negre D, et al. High levels of transduction of human dendritic cells with optimized SIV vectors. Mol Ther 2002; 5:283-290.
58. Follenzi A, Sabatino G, Lombardo A, et al. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum Gene Ther 2002; 13:243-260.
59. Dyall J, Latouche JB, Schnell S, Sadelain M. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood 2001; 97:114-121.
60. Piacibello W, Bruno S, Sanavio F, et al. Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Blood 2002; 100:4391-4400.
61. Sutton RE, Reitsma MJ, Uchida N, Brown PO. Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle dependent. J Virol 1999; 73:3649-3660.
62. Sadelain M, Frassoni F, Riviere I. Issues in the manufacture and transplantation of genetically modified hematopoietic stem cells. Curr Opin Hematol 2000; 7:364-377.
63. Kumar M, Keller B, Makalou N, Sutton RE. Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther 2001; 12:1893-1905.
64. Pawliuk R, Westerman KA, Fabry ME, et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 2001; 294:2368-2371.
65. Levasseur DN, Ryan TM, Pawlik KM, Townes TM. Correction of a mouse model of sickle cell disease. Blood 2003; 102:4312-4319.
66. Persons DA, Hargrove PW, Allay ER, et al. The degree of phenotypic correction of murine β-thalassemia intermedia following lentiviral-mediated transfer of a human γ-globin gene is influenced by chromosomal position effects and vector copy number. Blood 2003; 101:2175-2183.
67. Samakoglu S, Lisowski L, Budak-Alpdogan T, et al. A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nat Biotechnol 2006; 24:89-94. This study supports the use of RNA interference to regulate gene expression in hematopoietic cells.
68. Rivella S, Sadelain M. Therapeutic globin gene delivery using lentiviral vectors. Curr Opin Mol Ther 2002; 4:505-514.
69. May C, Rivella S, Chadburn A, Sadelain M. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. Blood 2002; 99:1902-1908.
70. Rivella S, May C, Chadburn A, et al. A novel murine model of Cooley's anemia and its rescue by lentiviral mediated human β-globin gene transfer. Blood 2003; 101:2932-2939.
71. Trudel M, De Paepe ME, Chretien N, et al. Sickle cell disease of transgenic SAD mice. Blood 1994; 84:3189-3197.
72. Paszty C, Brion CM, Manci E, et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 1997; 278:876-878.
73. Levasseur DN, Ryan TM, Reilly MP, et al. A recombinant human hemoglobin with anti-sickling properties greater than fetal hemoglobin. J Biol Chem 2004; 279:27518-27524.
74. He S, Russell JE. Anti-sickling effects of an endogenous human alpha-like globin. Nat Med 2004; 10:365-367.
75. Xu XS, Glazer PM, Wang G. Activation of human gamma-globin gene expression via triplex-forming oligonucleotide (TFO)-directed mutations in the gamma-globin gene 5′ flanking region. Gene 2000; 242:219-228.
76. Byun JH, Lan N, Long M, Sullenger BA, et al. Efficient and specific repair of sickle β-globin RNA by trans-splicing ribozymes. RNA 2003; 9:1254-1263.
77. Kohn DB. Gene therapy for genetic haematological disorders and immunodeficiencies. J Intern Med 2001; 249:379-390.
78. Rosenberg N, Jolicoeur P. Retroviral pathogenesis. In: Coffin AM, Hughes SH, Varmus HE, editors. Retroviruses. New York: Cold Spring Harbor Laboratory Press; 1997. pp. 475-585.
79. Berns Mikkers H, Allen J, Knipscheer P, et al. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet 2002; 32:153-159.
80. Suzuki T, Shen H, Akagi K, et al. New genes involved in cancer identified by retroviral tagging. Nat Genet 2002; 32:166-174.
81. Baum C, Dullmann J, Li Z, et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003; 101:2099-2114.
82. Kohn DB, Sadelain M, Dunbar C, et al. American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther 2003; 8:180-187.
83. Li Z, Dullmann J, Schiedlmeier B, et al. Murine leukemia induced by retroviral gene marking. Science 2002; 296:497.
84. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302:415-419.
85. Kohn DB, Sadelain M, Glorioso JC. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 2003; 3:477-488.
86. Dave UP, Jenkins NA, Copeland NG. Gene therapy insertional mutagenesis insights. Science 2004; 303:333.
87. Sadelain M. Insertional oncogenesis in human gene therapy: how much of a risk? Gene Ther 2004; 11:567-573.
88. Rivella S, Callegari JA, May C, et al. The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J Virol 2000; 74:4679-4687.
89. Emery DW, Yannaki E, Tubb J, Stamatoyannopoulos G. A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc Natl Acad Sci USA 2000; 97:9150-9155.
90. Yannaki E, Tubb J, Aker M, et al. Topological constraints governing the use of the chicken HS4 chromatin insulator in oncoretrovirus vectors. Mol Ther 2002; 5:589-598.
91. Emery DW, Yannaki E, Tubb J, et al. Development of virus vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo. Blood 2002; 100:2012-2019.
92. Chang JC, Ye L, Kan YW. Correction of the sickle cell mutation in embryonic stem cells. Proc Natl Acad Sci USA 2006; 103:1036-1040. The embryonic stem cell technology suggests that a therapeutic cloning approach may be feasible for treatment of sickle cell anemia.